Abstract: A method of leasing a power storage includes obtaining, for a vehicle including a power storage, a value of the power storage based on a capacity retention rate of the power storage, determining an insurance fee for a user of the vehicle to receive an insurance service relating to replacement of the power storage based on an accident risk of the vehicle, and determining a lease fee of the power storage based on the value of the power storage and the insurance fee.

Abstract: A server (management apparatus) includes: a communication unit (first acquisition unit) that acquires a request regarding adjustment of electric power supply-and-demand in a power grid; and a processor (controller) that performs, based on the request, control to notify, a user of an electrically powered vehicle, of a replacement cost required for battery replacement at a battery station (battery replacement apparatus). When charging with electric power of the power grid is requested and a battery (first battery) of the electrically powered vehicle has an SOC lower than the SOC of a battery (second battery) having a maximum SOC to be used for charging, among a plurality of batteries (second batteries), the processor performs control to notify the user of the replacement cost lower than a normal replacement cost.

Abstract: A server includes a communication unit (first communication unit) (second communication unit) that receives information about a request for adjustment of power supply-and-demand in a power grid. The server includes a processor (controller) that predicts a schedule of replacement of a battery (first battery) at a battery station (battery replacement apparatus). The processor specifies, based on the schedule, a battery (second battery) available for charging or discharging for the request for adjustment, and determines, based on the specified battery, whether or not it is possible to respond to the request for adjustment.

Abstract: [Problem] To provide a compound useful as a novel agent which is excellent in preventing and/or treating cannabinoid receptor type 2-related diseases, based on agonist action on a cannabinoid receptor type 2 [Means for Solution] The present inventors conducted thorough investigation regarding compounds having agonist action on a cannabinoid receptor type 2. They confirmed that the fused ring pyridine compound of the present invention has excellent agonist action on the cannabinoid receptor type 2, thereby completing the present invention. The fused ring pyridine compound of the present invention has agonist action on the cannabinoid receptor type 2, and can be used as an agent for preventing and/or treating cannabinoid receptor type 2-related diseases, for example, inflammatory diseases and pain.

Abstract: This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease.

Abstract: This invention relates to novel heterocyclic carboxamide derivatives and salts thereof. More particularly, it relates to novel heterocyclic carboxamide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease.

Abstract: This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease.

Abstract: The present invention relates to a compound of the formula (I) wherein R1 is optionally substituted aryl; R2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted lower cycloalkyl, optionally substituted aryloxy, optionally substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from optionally substituted aryl or optionally substituted heteroaryl; X is bivalent residue derived from the group consisting of cycloalkene, naphthalene, unsaturated 5 or 6-membered heteromonocyclic group, each of which is optionally substituted, and substituted benzene; Y is -(A1)m1-(A2)m2-; and Z is direct bond or piperazine, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

Abstract: The present invention relates to compounds of the formula (I) wherein X1 is wherein R1, R2 and R10 are independently hydrogen or a suitable substituent; R11 and R12 are independently hydrogen or a suitable substituent; R is unsaturated 5 to 6-membered heteromonocyclic group; A is direct bond or —NH—; X2 is monocyclic arylene, unsaturated 5 to 6-membered heteromonocyclic group or cycloalkenylene; Y is bivalent group selected from ethylene, trimethylene and vinylene, wherein CH2 is optionally replaced by NH or O, and CH is optionally replaced by N; and Z is —(CH2)n—, —CO—(CH2)m—, —CH═CH— or —CO—NH—, wherein n is 1, 2 or 3 and m is 1 or 2, or a salt thereof. The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

Abstract: To provide a browse information management system capable of flexibly controlling concealment areas of confidential portions in accordance with a user's browse authority level with respect to browse information including character strings, images, animations, or the like without time and labor required for maintenance such as response to new users. In the browse information management system comprising a mask layer data selecting means and a mask layer data combining means, the selecting means selects a single or plurality of pieces of mask layer data, in accordance with a user's browse authority level, from among a plurality of pieces of mask layer data in which concealment areas are drawn. The combining means combines the single or plurality of pieces of mask layer data selected by the selecting means with respect to original data that is browse information. Then, the user is provided by performing a concealing process to the browse information.

Abstract: A compound of the formula (I) 1

Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are each independently lower alkyl lower alkenyl, acyl, amino, lower alkoxy, lower cycloalkyloxy, aryl, aryloxy, sulfooxy, mercapto, sulfo, hydrogen, halogen, nitro, cyano or hydroxy, or may form a ring structure; Q1 is N or CH; L is optionally substituted unsaturated 3 to 10-membered heterocyclic group; X is optionally substituted monocyclic arylene or monocyclic heteroarylene; Y is -(A1)m-(A2)n-(A4)k-; Z is directbond, —CH2-, —NH— or —O—; and R is hydrogen or lower alkyl, or a salt thereof The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

Abstract: A compound of the formula: wherein R1 is amino or protected amino; R2 is hydrogen, lower alkyl or hydroxy protective group; R3 is carboxy or protected carboxy; R4 is an unsubstituted 5, 6 or 7-membered heteromonocyclic group containing two nitrogen atoms as heteroatoms, and which optionally further contains one oxygen or sulfur atom; or R4 is said 5, 6 or 7-membered heteromonocyclic group substituted by 1 to 4 groups selected from the group consisting of lower alkyl, lower alkoxy, lower alkylthio, lower alkylamino, cyclo(lower)alkyl, cyclo(lower)alkenyl, halogen, amino, protected amino, protected hydroxy, cyano, nitro, carboxy, hydroxy(lower)alkyl, amino(lower)alkyl, and carbamoyloxy; and n is 1 or 2.

Abstract: A novel crystal of 7&bgr;-[2-(2-aminothiazol-4-yl)-2-(Z)-(hydroxyimino)acetamido]-3-[pyrazol-4-yl)methylthio]3-cephem-4-carboxylic acid or a salt thereof.

Abstract: A novel crystal of 7&bgr;-[2-(2-aminothiazol-4-yl)-2-(Z)-(hydroxyimino)acetamido]-3-[pyrazol-4-yl)methylthio]3-cephem-4-carboxylic acid or a salt thereof.

Abstract: Compounds of the formula: ##STR1## wherein R is a group of the formula: ##STR2## in which R.sup.3 and R.sup.4 are each lower alkyl or R.sup.3 and R.sup.4 are linked together to form C.sub.3 -C.sub.6 alkylene, A is lower alkylene, and R.sup.5 is hydroxy or a protected hydroxy group;or a group of the formula: ##STR3## in which R.sup.6 is lower alkyl, R.sup.7 and R.sup.8 are each hydroxy or a protected hydroxy group, and Y is N or CH, and salts thereof are intermediates for cephem compounds which show antimicrobial activities and which are useful in the treatment of microbial infections.

Abstract: Cephem compounds of the formula: ##STR1## wherein R.sup.1 is amino or a protected amino group,Z is N or CH,R.sup.2 is lower alkyl, mono(or di or tri)halo(lower)alkyl, lower alkenyl, lower alkynyl, phenyl, naphthyl, phenyl(lower)alkyl, carboxy(lower)alkyl or protected carboxy(lower)alkyl, andR is a group of the formula: ##STR2## in which R.sup.3 and R.sup.4 are each lower alkyl,A is lower alkylene, andR.sup.5 is hydroxy or a protected hydroxy group; or pharmaceutically acceptable salts thereof show antimicrobial activities and are useful in the treatment of microbial infections.

Abstract: A compound represented by the following general formula: ##STR1## which is useful as an intermediate for production of a clinically excellent synthetic antibacterial, a salt thereof, and a process for producing the same.In said formula,R.sup.1 is a hydrogen atom or a carboxyl-protecting group;R.sup.2 is a hydrogen atom or a lower alkyl group;X.sup.1 is a hydrogen atom or a halogen atom;X.sup.2 is a halogen atom;X.sub.a.sup.5 is a hydrogen atom or a halogen atom;A is a methylene group; a group of >CH--COOR.sup.4, etc.,in which R.sup.4, R.sup.5 and R.sup.6 each are a hydrogen atom or a carboxyl-protecting group;B is a methylene group or a carbonyl group;provided that both A and B must not be methylene groups at the same time.

Abstract: Cephem compounds having the following formula are disclosed: ##STR1## R.sup.1 =amino or protected amino R.sup.2 =an organic group ##STR2## R.sup.6 =lower alkyl R.sup.7, R.sup.8 .dbd.OH or protected OHY.dbd.N or CHThe compounds are useful as antimicrobial agents.

Abstract: A steel composition particularly suitable for the manufacture of electric resistance welded pipes for use in most hostile environments and able to display excellent sour resistance and high toughness. The aluminum content of the steel composition is reduced to not more than 0.005%, while from 0.006 to 0.2% in total of one or both of titanium and zirconium is used instead for steel containing 0.0005 to 0.008% Ca. The steel, apart from iron and unavoidable impurities further contains:0.01 to 0.35% C0.02 to 0.5% Si0.1 to 1.8% Mnnot more than 0.015% P, andnot more than 0.003% SCu, Ni, Cr, Mo, Nb and V may be added in appropriate amounts to enhance the steel performance.